In addition, a CRISPR/Cas9 KO of BEN domain-containing protein 3 (BEND3) upregulated efflux transporter breast cancer resistance protein (BCRP; ABCG2) and reduced the intracellular levels of TAK-243 and induced resistance in acute myeloid leukaemia (AML) cells [75]. This evidence concerns the gene BEND3 and acute myeloid leukemia.